IRVINE, Calif., Jan. 24, 2013 (GLOBE NEWSWIRE) -- Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today achievement of the CE (Conformite Europeenne) Mark of the Nellix® EndoVascular Aneurysm Sealing System for the treatment of patients with abdominal aortic aneurysms ("AAA"). Nellix is the first available endovascular aneurysm sealing ("EVAS") system. EVAS with Nellix is an advanced treatment strategy designed to simplify endovascular AAA procedures, treat a broad range of patients, and provide enhanced clinical outcomes. The Nellix System is not approved in the United States for either investigational use or commercial sale.
Endologix Receives CE Mark For Nellix(R) EndoVascular Aneurysm Sealing System
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts